Eltrombopag/Eltrombopag: Key Precautions When Using

1. Risk of liver decompensation: For patients with chronic hepatitis C, the risk of liver function decompensation may increase when Eltrombopag is used in combination with interferon and ribavirin. In particular, patients with lower albumin levels (<3.5g/dL) or higher Model for End-Stage Liver Disease (MELD) scores are at greater risk of liver decompensation when receiving eltrombopag plus antiviral therapy. Therefore, eltrombopag should also be discontinued when antiviral therapy is discontinued.

2. Risk of hepatotoxicity: Use of eltrombopag may increase the risk of serious and potentially life-threatening hepatotoxicity. For the treatment of thrombocytopenia (ITP), chronic hepatitis C-related ITP, and refractory severe aplastic anemia (AA), serum ALT, AST, and bilirubin levels should be measured before initiating eltrombopag and every 2 weeks during dose adjustments. After determining the stable dose, measure it once a month.

3. Thrombosis/thromboembolic complications: Eltrombopag may cause an increase in platelet count, thereby increasing the risk of thrombosis/thromboembolism. This risk is not only present with high platelet counts but may occur even with low or normal platelet counts. Particular caution should be exercised when using eltrombopag in patients with known risk factors for thromboembolism, such as factor V Leiden, ATIII deficiency, antiphospholipid syndrome, or chronic liver disease. To reduce this risk, use of eltrombopag to normalize platelet counts is not recommended, but recommended dose adjustment guidelines should be followed to maintain target platelet counts.

4. Cataract risk: In clinical trials of eltrombopag, some patients had eye problems before treatment and developed cataracts or worsened during treatment. Additionally, the development of cataracts has been observed in animal studies. Therefore, a baseline eye examination should be performed before using eltrombopag and regularly monitored for signs and symptoms of cataracts during treatment.

5. Risk of death and myelodysplastic syndrome progression to acute myeloid leukemia: A clinical trial in patients with International Prognostic Scoring System (IPSS) grade 1, 2, or high-risk myelodysplastic syndrome (MDS) with thrombocytopenia was terminated early due to lack of efficacy and safety data. The trial found that patients treated with eltrombopag had a 42% increased risk of death and a 166% increased risk of progression to acute myeloid leukemia (AML) compared with placebo. Therefore, in patients with MDS, eltrombopag should be used with special caution and close attention should be paid to its potential side effects.

In general, eltrombopag/Eltrombopag is an effective drug, but you must pay attention to the above risks when using it, and follow your doctor's recommendations and guidance to ensure patient safety and therapeutic effects.